Cresco Labs Delivers Q4 2025 Revenue of $162 Million and Sequential Margin Improvement
CHICAGO–(BUSINESS WIRE)– Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the fourth quarter ended and year ended December 31, 2025. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company’s investor website, here.
Fiscal Year 2025 Highlights
- Revenue of $656 million. Operating cash flow of $73 million and Free Cash Flow¹ of $38 million.
- Gross profit of $325 million. Adjusted gross profit¹ of $329 million; and an Adjusted gross margin¹ of 50.2%.
- SG&A of $218 million. Reduced Adjusted SG&A¹ by 5.7% year-over-year to $200 million, or 30.4%.
- Net loss of $140 million, which includes one-time, non-cash charges of $105 million related to the Company’s impairment of intangibles and goodwill associated with the write-down of the New York reporting unit and fair value adjustments to the California reporting unit related to the sale of Sonoma’s Finest.
- Adjusted EBITDA¹ of $157 million and Adjusted EBITDA margin¹ of 24.0%.
- Retained the No. 1 share position in multiple billion dollar markets for the full year.²
Fourth Quarter 2025 Highlights
- Fourth quarter revenue of $162 million. Fourth quarter operating cash flow of $27 million.
- Gross profit of $83 million. Adjusted gross profit¹ of $84 million; and an Adjusted gross margin¹ of 52.2%.
- SG&A of $57 million or 35.3% of revenue.
- Net loss of $89 million, which includes one-time, non-cash charges of $93 million related to the write-down of the New York reporting unit.
- Fourth quarter Adjusted EBITDA¹ of $40 million and Adjusted EBITDA margin¹ of 25.0%.
- Retained the No. 1 share position in multiple billion dollar markets.²
Management Commentary
“In Q4, we strengthened our financial foundation while expanding margins and generating meaningful cashflow. We delivered $162 million in revenue, $40 million in Adjusted EBITDA, and $27 million in operating cashflow, with sequential improvement across multiple profitability metrics. Our focused strategy continues to enhance our competitive position.”
“The cannabis industry is consolidating in real time, and Cresco Labs is operating from a position of strength – we continue to show that we win where we operate. We are intentionally building a productive cash-generating platform, balancing organic expansion with selective, accretive acquisitions while maintaining a strong balance sheet. With leading brand share, differentiated retail execution, and embedded operating leverage, Cresco Labs is positioned to capitalize on industry consolidation and federal reform to create long-term value for shareholders.”
¹See “Non-GAAP Financial Measures” at the end of this press release for more information regarding the Company’s use of non-GAAP financial measures.
²According to Hoodie Analytics.
Balance Sheet, Liquidity, and Other Financial Information
As of December 31, 2025, current assets were $259 million, including cash, cash equivalents, and restricted cash of $91 million. An additional $3 million of restricted cash was classified as a non-current asset. The Company had senior secured term loan debt, net of discount and issuance costs, of $311 million and a mortgage loan, net of discount and issuance costs, of $19 million.
Total shares on a fully converted basis to Subordinate Voting Shares were 491,585,556 as of December 31, 2025.
Conference Call and Webcast
The Company will host a conference call and webcast to discuss its financial results on Thursday, March 5, 2026, at 8:30am Eastern Time (7:30am Central Time). The conference call may be accessed via webcast or by dialing 1-833-470-1428 (US Toll Free) or 1-646-844-6383 (US Local), and providing access code 152399. Archived access to the webcast will be available for one year on Cresco Labs’ investor website, here.
